primary%20angle-closure%20glaucoma
PRIMARY ANGLE-CLOSURE GLAUCOMA
Primary angle-closure is the synechial or appositional closure of the anterior chamber angle secondary to multiple mechanisms resulting in raised intraocular pressure and structural changes in the eyes.
Iridotrabecular contact is the hallmark of primary angle-closure  and the most commonly identified sign which indicates that treatment is required.
It is defined by at least 180 degrees of iridotrabecular contact together with an elevated intraocular pressure or peripheral anterior synechiae or btoh
Primary angle-closure glaucoma is the presence of glaucomatous optic neuropathy.

Patient Education

  • Instruct patients to avoid medicines that cause pupillary dilatation & induce an acute angle-closure crisis (eg decongestants, adrenergic agents, anticholinergics, antipsychotics, antidepressants, motion sickness medications)
  • Teach patients on how to properly instill eye drops (intervals, lid closure, punctal occlusion)
    • Punctal occlusion & eyelid closure for at least 3 minutes
    • If ≥2 drops are to be instilled, wait at least 5 minutes between drops
    • Demonstrate the preferred method & ensure patient can do it
  • Communicate to the patient & family the importance of compliance since glaucoma is a chronic disease which requires continuous patient cooperation for successful management
  • Advise patients w/ family history of PAC to undergo regular eye screening examinations for this condition
  • Inform patients at risk for acute angle-closure about its symptoms & instruct them to notify immediately should these symptoms occur
  • Provide educational materials
Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
2 days ago
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.